Original Article Analysis of CDR3 polymorphism of T cell receptor by high-throughput sequencing in vitiligo patients

Pengfei Song*, Jing Wang*, Jiayuan Chen, Juan Xu, Qin He

Department of Dermatology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong Province, China. *Equal contributors and co-first authors.

Received March 29, 2018; Accepted May 10, 2018; Epub July 15, 2018; Published July 30, 2018

Abstract: Objective: To investigate the CDR3 polymorphism of T cell receptor (TCR) in patients with vitiligo by highthroughput sequencing and immune repertoire analysis. Methods: A total of 45 patients with vitiligo were included in the case group, and 28 healthy volunteers were enrolled in the control group. Fasting venous blood collection was performed in both groups. Upon the total RNA extraction of cells, reverse transcription was carried out. Design and synthesis of downstream primers for TCR beta chain constant gene (TRBC) and specificity upstream primers for TCR beta chain variable gene (TRBV) gene family with common fluorescent labeling were conducted. Polymerase chain reaction was used for amplification of CDR3 in TRBV family. The CDR3 polymorphism and length of TRBV family were analyzed by means of a capillary electrophoresis genescan. Based on the analysis results, 8 samples in case group and 7 samples in control group were selected for cloning and sequencing of the TRBV6 family. The polymorphism, variable and joining gene expression as well as the composition, structure, and function of amino acid in CDR3 were also analyzed and the expression ratio of clonotype was detected. Results: Analysis of capillary electrophoresis genescan showed that compared with the control group, the CDR3 polymorphism in case group was significantly decreased, and the expressive abundance of TRBV20-1, TRBV7-9, and TRBV2 genes was the highest in the samples. The expression of TRBV7-9, TRBV25-1, TRBV4-1, TRBV12-5 showed significant differences, with the difference of TRBV7-9 being the most significant. The expressive abundance of clonotypes in different individuals differed greatly. There was no preference difference for amino acids within the groups, but there was an obvious difference in amino acid structure and function between the two groups. Analysis of a hyper-expressed clone found that the samples were highly heterogeneous, but the sequence similarity was very low, which proved that the expression difference of TRBV7-9 was the most obvious between the groups. Conclusion: The CDR3 polymorphism in patients with vitiligo was significantly increased.

Keywords: Vitiligo, high-throughput sequencing, CDR3, polymorphism

Introduction

Vitiligo, as the most common depigmenting skin disease in clinic, is mainly caused by selective destruction of melanocytes, and it infects both adults and children [1, 2]. At present, the pathogenesis of this disease is not completely clear yet. Genetic factors, biochemical factors, melanocyte auto-destruction and autoimmune disorder are important known causes [3, 4]. A clinical study confirmed that most patients with vitiligo are complicated with autoimmune diseases, which further suggests that vitiligo has a certain correlation with immune response disorder [5]. Once the immune response of human skin is imbalanced, specific damage often appears in melanocytes, which is another important cause of vitiligo [6]. T cells, which participate in the immune response, are vital for the pathogenesis of autoimmune diseases [7]. Mature T cells express the T cell receptors (TCR), and complementarity determining region 3 (CDR3) is able to reflect the polymorphism of TCR the most. CDR3 polymorphism also helps T cells recognize numerous antigens in human body. Therefore, analysis of TCR CDR3 sequence can further assist us in identifying T cell antigens [8]. High-throughput sequencing technology has been widely used in recognizing TCR CDR3 repertoires of autoimmune diseases and tumors [9]. However, it has not been used for vitiligo. Thus, this study aims to analyze the polymorphisms of TCR CDR3 in patients with vitiligo and to provide a reference for clinic.

NameSequence (5'-3')TRBV1-SenseGCACAACAGTTCCCTGACTTGCACTRBV2-SenseTCATCAACCATGCAAGCCTGACCTTRBV3-SenseGTCTCTAGAGAGAGAAGAAGGAGCGCTRBV4-1-SenseACATATGAGAGTGGATTTGTCATTTRBV5-1-SenseTACTTCAGTGAGACACAGAGAAACTRBV5-2-SenseTTCCCTAACTATTAGCTCTGAGCTGTRBV7-SenseCCTGAATGCCCCAACAGCTCTCTRBV7-SenseCCTGAATGCCCCAACAGCTCCTRBV7-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACATTCCGTRBV1-SenseCCTCAAAATCTCCAGACAAAGCTCACTRBV10-SenseCCTCAAAAACTCATCCTGTACCTTTRBV10-SenseCCTCCAAAAACTCACCAGATTRBV12-5-SenseTCACAGTCTCCAGAATAAGGACGTRBV13-1-SenseAAGGAGAAGTCTCAGATTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGGAATTRBV15-SenseAAGGAGTCTAAACAGGAAGAGCATRBV18-SenseGATGAGTCAGAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV20-SenseGATGAGTCCGAAAAGAGAACGAACCCTGCTRBV21-SenseCAAAGCCCTTCAAGGAATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseGATCGATTCTCAGCCAAAGGAATRBV19-SenseCAAAGCCCTTCAAGGACATTRBV23-SenseGACGATTTTAACAATGAAGCAGACTRBV23-SenseCAAAGGCCTTCAATGAACAGGAACACAGTRBV23-SenseCAAAAGCCCTTCACAGGACATTRBV2								
TRBV2-SenseTCATCAACCATGCAAGCCTGACCTTRBV3-SenseGTCTCTAGAGAGAAGAAGAAGAAGCGCTRBV4-1-SenseACATATGAGAGTGGATTTGTCATTTRBV5-1-SenseTACTTCAGTGAGACACAGAGAAACTRBV5-2-SenseTTCCCTAACTATTAGCTCTGAGCTGTRBV6-SenseAGGCCTGAGGGATCCGTCTCTRBV7-SenseCCTGAATGCCCCAACAGCTCCGTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCCTCAAAAACTCATCCTGTACCTTTRBV10-SenseCCTCAAAACTCCAGACAAAGCTCACTRBV12-SenseCCTCAAAACTCCACAGAATAAGGACGTRBV13-SenseCCTCCAAAAACTCCAGATTRBV13-1-SenseAAGGAGAAGTCCCCAATTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGGAATTRBV15-SenseAAGGAGTCTAAACAGGATGAGCCTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV20-SenseGATTCACAGTTGCCTAAGGATRBV21-SenseGATCCAAGTTGCCTAAGGATRBV22-SenseCAAAAGCCCTTCAACAGGAATATTCGATRBV23-SenseGATCGATTCTCAGACTGAACACAGTRBV23-SenseGATCGATTCTCAGACACACAGACATTRBV25-1-SenseCAAAAGCCCTTCACAGACACACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	Name	Sequence (5'-3')						
TRBV3-SenseGTCTCTAGAGAGAAGAAGAAGGAGCGCTRBV4-1-SenseACATATGAGAGTGGATTTGTCATTTRBV5-1-SenseTACTTCAGTGAGACACAGAGAAACTRBV5-2-SenseTTCCCTAACTATTAGCTCTGAGCTGTRBV6-SenseAGGCCTGAGGGATCCGTCTCTRBV7-SenseCCTGAATGCCCCAACAGCTCCGTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTCAAAATCTCCAGACAAAGCTCACTRBV10-SenseCCTCAAAAACTCATCCTGTACCTTTRBV11-SenseCCTCAAAAACTCATCCTGTACCTTTRBV12-S-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseTCAACAGTCTCCAGAATAAGGACGTRBV13-1-SenseGGTGAGGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV15-SenseAAGGAGAAGTCTAACAGGAAGTCCTRBV16-SenseAAGGAGTCTAAACAGGAAGGCTTRBV18-SenseGCTCTCGAAAAGAGAAGAGGAATTRBV18-SenseGATGAGTCAAACAGGAAGGCACAGGCTTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATCGATTCCAAGTGCCAAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCCAAGTGACACAGGACTRBV23-SenseGATCGATTCTCAACAGAAGCAGACTRBV24-SenseAAAGATTTTAACAATGAAGCAGAACTRBV25-1-SenseCAAAAGCCCTTCACAGGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV1-Sense	GCACAACAGTTCCCTGACTTGCAC						
TRBV4-1-SenseACATATGAGAGTGGATTTGTCATTTRBV5-1-SenseTACTTCAGTGAGACACAGAGAAACTRBV5-2-SenseTTCCCTAACTATTAGCTCTGAGCTGTRBV6-SenseAGGCCTGAGGGATCCGTCTTRBV7-SenseCCTGAATGCCCCAACAGCTCCTRBV7-9-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV10-SenseCCTCAAAACTCACCTGTACCTTTRBV11-SenseTCACACAGTCTCCAGAATAAGGACGTRBV12-5-SenseACGGAGAAGTCTCAGATTRBV13-1-SenseAAGGAGAAGTCCCCAATTRBV13-2-SenseGTCTCGAAAAGAGAGAGAGCCTRBV13-2-SenseGTGTCTCGAAAAGAGAAGAGGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAGGAGTCTAAACAGGAAGAGAGAGCTRBV17-SenseCAGATAGTAAACAGGAAGAGAGAGAGCCTRBV17-SenseGATGAGTCAGGAATGCCAAAGGAATRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATCCATTCCAGCTCAACAGTRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseCAAAAGCCCTTCAACAGAACGCACACTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV2-Sense	TCATCAACCATGCAAGCCTGACCT						
TRBV5-1-SenseTACTTCAGTGAGACACAGAGAAACTRBV5-2-SenseTTCCCTAACTATTAGCTCTGAGCTGTRBV6-SenseAGGCCTGAGGGATCCGTCTCTRBV7-SenseCCTGAATGCCCCAACAGCTCTCTRBV7-9-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGAACAAAGCTCACTRBV10-SenseCCTCAAAAACTCATCCTGTACCTTTRBV11-SenseCCCAAAAACTCATCCTGTACCTTTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseGGTGAGGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGAGAATTRBV15-SenseAAGGATCTCAGAAAGAGAGAGAGAGAGTRBV15-SenseAAGGATCTAAACAGGATGAGTCCTRBV16-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseGATTCACAGTTGCCTAAGGATRBV20-SenseGATCGATTCTCAGCTCAAGGAATRBV21-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseCAAAGCCCTTCACAGACACACAGTRBV25-1-SenseCAAAAGCCCTTCACAGACACACAGACACACACACACACAC	TRBV3-Sense	GTCTCTAGAGAGAAGAAGGAGCGC						
TRBV5-2-SenseTTCCCTAACTATTAGCTCTGAGCTGTRBV6-SenseAGGCCTGAGGGATCCGTCTCTRBV7-SenseCCTGAATGCCCCAACAGCTCCCTRBV7-9-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCCCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseGGTGAGGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV15-SenseAAGGATCTCTCGACAGGCACAGGCTTRBV16-SenseAAGGATCTCAGAATGAGAGAGAGAGAGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAAGAGAGAAGTRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseGATGCCCCAAGAACGCACCCTGCTRBV20-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAAGAGATCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV23-SenseCAAAGACTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseAAGGGGTCTAAATGCAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV4-1-Sense	ACATATGAGAGTGGATTTGTCATT						
TRBV6-SenseAGGCCTGAGGGATCCGTCTCTRBV7-SenseCCTGAATGCCCCAACAGCTCTCTRBV7-9-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCTCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCCCCAATTRBV13-1-SenseAAGGAGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGGGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAAGCCCTTCACAGACACACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseAAGGGGTCTACATGGCAACTGAPDH SenseAGGGGTCTACATGGCAACT	TRBV5-1-Sense	TACTTCAGTGAGACACAGAGAAAC						
TRBV7-SenseCCTGAATGCCCCAACAGCTCTCTRBV7-9-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCTCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseGGTGAGGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV15-SenseGTCTCGAAAAGAGAGAGAGGAATTRBV15-SenseAAGGAGTCTAAACAGGCACAGGCTTRBV16-SenseAAGGATCTTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseGATGAGTCAGGAATGCCAAAGGAATRBV20-SenseGATTCACAGTTGCCTAAGGATRBV21-SenseGATTCACAGTTGCCTAAGGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAAGCCCTTCACAGACACAGTRBV25-1-SenseCAAAAGCCCTTCACAGACACACTRBC Anti-SenseAAGGGGTCTACATGGCAACTTRBC Anti-SenseAGGGGTCTACATGGCAACT	TRBV5-2-Sense	TTCCCTAACTATTAGCTCTGAGCTG						
TRBV7-9-SenseTTGGCGCGCATGGGCACCAGCCTCCTRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCTCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCCAGATTRBV13-1-SenseGGTGAGGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV15-SenseAAGGATCTCCGACAGGCACAGGCTTRBV16-SenseAAGGATCTCAGAAAGAGAAGAGGAATTRBV17-SenseCAGATAGTAAACAGGATGAGTCCTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAGAAGTCCAGGAATGCCAAAGGAAGTCAAGAGAGAACTCCTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGATTCACAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGACACACAGTRBV25-1-SenseCAAAAGCCCTTCACAGACACATRBC Anti-SenseAAGGGGTCTAAATGCAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV6-Sense	AGGCCTGAGGGATCCGTCTC						
TRBV8-SenseATTTACTTTAACAACAACTTCCGTRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCTCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseAAGGAGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGGGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGGAGTCAAACAGGAAGAGAGAGAGAGTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAAATRBV19-SenseCAAAGCCCCAAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAAGCCCTTCACAGACACATRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseAGGGGTCTAACATGGCAACTGAPDH SenseAGGGGTCTACATGGCAACT	TRBV7-Sense	CCTGAATGCCCCAACAGCTCTC						
TRBV9-SenseCCTAAATCTCCAGACAAAGCTCACTRBV10-SenseCTCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseAAGGAGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV19-SenseGATTCACAGGTGCCCCAGAATCTCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGACACACAGTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseAAGGGGTCTAAATGGCAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV7-9-Sense	TTGGCGCGCATGGGCACCAGCCTCC						
TRBV10-SenseCTCCAAAAACTCATCCTGTACCTTTRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseAAGGAGGTACAACTGCCTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGAGAGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGATTCACAGTTGCCTAAGGATRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV25-1-SenseCAAAAGCCCTTCACAGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGAACACAAGAACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseAGGGGTCTACATGGCAACTGAPDH SenseAGGGGTCTACATGGCAACT	TRBV8-Sense	ATTTACTTTAACAACAACTTCCG						
TRBV11-SenseTCAACAGTCTCCAGAATAAGGACGTRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseAAGGAGAAGTCCCCAATTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGGAATTRBV15-SenseAAGGATCTCAGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGACACACAGTRBV25-1-SenseCAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV9-Sense	CCTAAATCTCCAGACAAAGCTCAC						
TRBV12-5-SenseAAAGGAGAAGTCTCAGATTRBV13-1-SenseAAGGAGAAGTCCCCAATTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGAGAGAGATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGACACATRBV25-1-SenseCAAAAGCCCTTCACAGACAACACGAPDH SenseAGGGGTCTACATGGCAAACT	TRBV10-Sense	CTCCAAAAACTCATCCTGTACCTT						
TRBV13-1-SenseAAGGAGAAGTCCCCAATTRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGAGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGACACACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV11-Sense	TCAACAGTCTCCAGAATAAGGACG						
TRBV13-2-SenseGGTGAGGGTACAACTGCCTRBV14-SenseGTCTCGAAAAGAGAAGAGAGGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV16-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGAACGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV12-5-Sense	AAAGGAGAAGTCTCAGAT						
TRBV14-SenseGTCTCGAAAAGAGAGAAGAGAGGAATTRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGAAGCAACGCACCTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV13-1-Sense	AAGGAGAAGTCCCCAAT						
TRBV15-SenseAGTGTCTCTCGACAGGCACAGGCTTRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGAACACATRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV13-2-Sense	GGTGAGGGTACAACTGCC						
TRBV16-SenseAAAGAGTCTAAACAGGATGAGTCCTRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV14-Sense	GTCTCGAAAAGAGAAGAGGAAT						
TRBV17-SenseCAGATAGTAAATGACTTTCAGTRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseCAAAGCCCTTCACAGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV15-Sense	AGTGTCTCTCGACAGGCACAGGCT						
TRBV18-SenseGATGAGTCAGGAATGCCAAAGGAATRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV16-Sense	AAAGAGTCTAAACAGGATGAGTCC						
TRBV19-SenseCAATGCCCCAAGAACGCACCCTGCTRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV17-Sense	CAGATAGTAAATGACTTTCAG						
TRBV20-SenseGCTCTGAGGTGCCCCAGAATCTCTRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV18-Sense	GATGAGTCAGGAATGCCAAAGGAA						
TRBV21-SenseGATTCACAGTTGCCTAAGGATRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV19-Sense	CAATGCCCCAAGAACGCACCCTGC						
TRBV22-SenseCAGAGAAGTCTGAAATATTCGATRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV20-Sense	GCTCTGAGGTGCCCCAGAATCTC						
TRBV23-SenseGATCGATTCTCAGCTCAACAGTRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV21-Sense	GATTCACAGTTGCCTAAGGA						
TRBV24-SenseAAAGATTTTAACAATGAAGCAGACTRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV22-Sense	CAGAGAAGTCTGAAATATTCGA						
TRBV25-1-SenseCAAAAGCCCTTCACAGACATTRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV23-Sense	GATCGATTCTCAGCTCAACAG						
TRBC Anti-SenseTTCTGATGGCTCAAACACGAPDH SenseAGGGGTCTACATGGCAACT	TRBV24-Sense	AAAGATTTTAACAATGAAGCAGAC						
GAPDH Sense AGGGGTCTACATGGCAACT	TRBV25-1-Sense	CAAAAGCCCTTCACAGACAT						
	TRBC Anti-Sense	TTCTGATGGCTCAAACAC						
GAPDH Anti-Sense CGACCACTTTGTCAAGCTCA	GAPDH Sense	AGGGGTCTACATGGCAACT						
	GAPDH Anti-Sense	CGACCACTTTGTCAAGCTCA						

 Table 1. Sequence of primers

Materials and methods

Subjects

The whole blood of 45 patients with vitiligo (case group) was collected. Among them, there were 28 males and 17 females, aged 8-73 years, with an average age of 34 ± 4.8 years and course of disease of 26 ± 11.8 months. A total of 28 healthy volunteers were enrolled in control group, including 13 males and 15 females with an average age of 32 ± 3.2 years. All vitili-go patients received none systemic treatment such as immunomodulatory drugs, photochemical therapy and corticosteroids in one month. The healthy controls did not have a positive family history of psoriasis or other autoimmune

diseases. There was no significant difference in age and gender between the two groups. All fasting venous blood collected from patients and controls was delivered to the laboratory and processed within 4 hours. This study was approved by the Ethics Committee of The Eighth Affiliated Hospital, Sun Yat-sen University. Informed consents were obtained from all subjects and their family members.

ARM-PCR

Total RNA of blood was extracted, and its concentration was measured according to the operating instructions of kit. The cDNA template was synthesized by reverse transcription reaction in a polymerase chain reaction (PCR) amplification device according to the instructions of reverse transcription kit (TransGen Biotech, Beijing). PCR amplification was performed for the CDR3 of TCR beta chain variable gene (TRBV). The reaction system included: 2 μ L of cDNA template, 2 μ L of upstream and downstream primers for TRBV, 30 µL of purified water, 5 µL of 2 mM dNTP, 5 µL of 10 × buffer, 3 µL of MgCl, and 0.25 µL of Tag DNA polymerase. After 30 consecutive cycles of 94°C for 1 min, 55°C for 1 min, 72°C for 1 min and 72°C for 8 min, it was stored at -20°C for standby application. The primers were synthesized by Bioengineering Co., Ltd. See Table 1 [10].

DNA purification and recovery

Principal component analysis (PCA) was used to analyze the expression of the top10 genes, and the genes with the most obvious expression differences were selected for analysis. The PCR products in CDR3 of the TRBV7-9, TRBV25-1, TRBV4-1, TRBV12-5 family (with the most significant differences) were purified, recovered, concentrated, and amplified. They were purified by 3% agarose gel electrophoresis for 1 h. The target DNA strips of those gene families on the gel were removed by a clean, sharp scalpel, and the recovery of DNA fragment was conducted according to the instructions of gel extraction kit (CW0524S, KWBio, Beijing, China).

High-throughput sequencing on Roche 454 GS FLX

The amplified CDR3 adaptors were ligated to the receptor repertoire, and the linkers were

Label	Case	Control	t	Р
Total input sequences	24,260,922±11,092,587	19,924,033±11,657,515	1.593	0.115
Total good sequences	22,286,717±9,353,904	14,833,522±12,613,209	2.891	0.005
Clones	39,407±26,170	76,623±44,961	4.476	<0.001
Clones with stops %	7.01±1.92	6.75±0.53	0.698	0.487
Clusterized clones %	75.32±20.32	67.39±10.67	1.905	0.060
V mappings found % of total	95.54±4.45	93.57±8.93	1.254	0.214
V not determined clones %	3.60±1.74	3.47±1.53	0.324	0.746
J mappings found % of total	93.85±4.79	92.42±9.60	0.846	0.400
J not determined clones %	0.18±0.28	0.13±0.05	0.933	0.353
Mapped LQ reads % of good	0.61±0.53	0.62±0.19	0.095	0.923
Out of frame clones	40.15±7.54	43.07±12.64	1.238	0.219
Sequencing information utilization %	92.50±5.00	89.23±10.33	1.814	0.073

Table 2. Sequence analysis

Note: Total input sequences: pair-end 150 bp, successful Merge reads; total good sequences: CDR3 reads in total input sequences; clones: clone numbers; clones with stops: clonotype with CDR3 termination tag; clusterized clones %: MiTCR software was used for extracting CRD3, which clustered the resulting clonotype, some clonotypes with low quality and poor support would be clustered in the higher ones near them (more details refer to the MiTCR software instructions). V mappings found % of total: ratio of reads that could be aligned to V genes; V not determined clones %: the ratio of V genes could not be determined; J mappings found % of total: ratio of reads that could be aligned to J genes; J not determined clones %: the ratio of J genes could not be determined; mapped LQ reads % of good: the reads could be aligned to the order of magnitude; out of frame clones: clonotype number of outliers.

ligated to the DNA fragments by molecular biology techniques. The single-stranded DNA library was immobilized on DNA capture beads. Specific linkers were used to ensure the successful binding of the magnetic beads to the DNA fragments. Upon successful emulsification and dispersion by amplification reagents, the magnetic bead library formed fragments containing specific sample DNA and magnetic beads. Each fragment was independently amplified in its own microreactor without the influence of other sequences, and the amplification proceeded in parallel with multiple copies. Afterwards, the emulsion mixture was broken, and specific fragment of each magnetic bead was generated. The TRBV family CDR3 immune repertoire was successfully established.

Statistical analysis

SPSS 19.0 was used for data analysis. The t-test was used to compare the polymorphisms between the two groups, and the Mann-Whitney test was used to evaluate the differences of polymorphism among TRVB families. Peak Seanner Sofb, varev 1.0 software was used to analyze sequencing data. PCA was used to analyze the differences of principal components.

Results

Comparison of the reads and clone numbers in CDR3 between two groups

Based on the analysis of sequence data (**Table 2**), it was found that in the case group, the reads of Merge at CDR3 was significantly higher than that in the control group, while the clone number in the case group was significantly less than that in the control group, indicating that the clonotype polymorphism of the case group was significantly lower than that of the control group (P<0.05).

Comparison of expression quantity and categories of CDR3 clonotype between the two groups

The expression quantity and categories in CDR3 clonotype of both groups were shown in **Figure 1**. Compared with the control group, the expression quantity of clonotype in the case group increased significantly, but the category of clonotype decreased significantly. Therefore, there were high expression quantity and less categories of clonotype in the case group, demonstrating that the CDR3 polymorphism of the case group was significantly decreased compared with the control group.



Figure 1. Analysis of clonotype expression quantity and categories of samples in two groups. A: Distribution of total clonotype number of each sample; B: Distribution of clonotype numbers with expression quantity more than 2; C: Distribution of total clonotype categories of each sample; D: Distribution of clonotype categories with expression quantity more than 2.

Analysis of CDR3 VJ gene

According to the expression richness analysis of CDR3 variable (V) and joining (J) genes, we found that the V and J genes in both groups had the same type of use, but the cumulative frequency was slightly different. TRBV20-1, TRBV7-9, TRBV2 expressed the most abundant among the samples (**Figure 2A** and **2B**). The distributions of the first principal component and the second principal component of the V gene were significantly different between the two groups (**Figure 2C**), indicating a significant difference in the compositional proportions. After the analysis of the expression of top10 genes, the main differences were found in the expression of TRBV7-9, TRBV25-1, TRBV4-1, and TRBV12-5, with the most significant difference in TRBV7-9 (**Figure 2D**).

Analysis of CDR3 amino acid

Analysis of amino acid composition, structure and function in CDR3 revealed that the length distribution of total clonotype was disordered, while the length distribution of unique clonotype was relatively uniform (**Figure 3A**), indicating that the expression abundances of clonotypes varied greatly among individuals. The difference might relate to different immune environments. The correlation coefficient between different samples was high with strong consistency (**Figure 3B**). The distribution of the amino acid composition ratio of clonotype Analysis of CDR3 polymorphism of TCR in vitiligo patients



Figure 2. Analysis of CDR3 VJ genes. A: Analysis of expression richness of V gene; B: Analysis of expression richness of J gene; C: Composition analysis of V gene; D: Heat map of differential V gene (t-test, P<0.05). The color shades represent the up-regulation (>0) or down-regulation (<0) of gene expression in each sample; vertical indicators indicate different gene families, and horizontal indicators represent different samples.

CDR3 showed that there was no significant difference in the amino acid composition ratio among the groups (**Figure 3C**), indicating that there was basically no preference for amino acids in different groups of samples. Cluster analysis found that the amino acids in control group and case group were significantly different in structure and function (**Figure 3D**).

Analysis of hyperexpressed clone

We tested the expression ratio of all clonotypes. The clonotype with a ratio of more than 1% per sample was considered to be a hyperexpressed clone. Analysis showed that the samples were highly heterogeneous, but the sequence similarity was very low (**Figure 4A**). Analysis of the expression of related sequence V genes showed that the expressions of TRBV7-9 were significantly different among groups (**Figure 4B**), so it was concluded that TRBV7-9 might relate to disease phenotype.

Discussion

Vitiligo as a common generalized depigmenting skin or acquired localized disease, appears at all parts of the body due to the dysfunction of skin melanocytes [11-13]. At present, studies have confirmed from the perspective of molecular immunity that T cells may be closely related to the pathogenesis of vitiligo. The mechanism may be that CD4⁺ T and CD8⁺ T cells are affected by surface-specific antigens of melanocytes, so their proliferation and activation are increased, and then, CD4⁺ T and CD8⁺ T secrete other cytokines that promote the proliferation of other immune cells and damage the melanocytes in vivo [14, 15]. The study of the mechanism of T cells in the pathogenesis of vitiligo is of great significance for the evaluation and treatment of this disease.

TCR presents on the surface of each T cell, and TCR3 is the most responsive to the diversity of TCR [16, 17]. Therefore, in this study, TCR CDR3 sequence was analyzed from the perspective of high-throughput sequencing. These results can help us better understand the pathogenesis of vitiligo and find a better target for the treatment of vitiligo. Understanding the polymorphism of TCR CDR3 repertoires and amino acids as well as the dynamic changes from a technical and theoretical perspective is the key to understanding the diversity of T cells [18, 19]. Comparison of the reads and clone number in the CDR3 between the two groups found that in the case group, the reads of Merge at CDR3 was significantly higher than that in the control group, while the clone number in the case group was significantly lower than that in the control group, indicating that the clonotype polymorphism of the case group was significantly lower than that of the control group (P<0.05), and the TCR CDR3 polymorphism in vitiligo patients was abnormal compared with the normal people. Analysis of the richness of VJ gene expression in CDR3 revealed that the gene expression differences between the two groups mainly appeared in TRBV7-9, TRBV25-1, TRBV4-1, and TRBV12-5, with TRBV7-9 being the most significant. Analysis of the amino acid composition, structure and function of the CDR3 showed that expression abundance of clonotype in different people varied widely. Sui et al. had the same finding when analyzing the amino acid composition in the CDR3 of TCR: this might relate to the different immune environment [20]. The cluster analysis showed that the amino acids in control group and case group were significantly different in structure and function, which might be the reason for the expression difference of the TCR CDR3 sequence between the two groups. Analysis of hyper-expressed clone of the related sequence V genes demonstrated that TRBV7-9 had the most significant difference between vitiligo patients and healthy controls, suggesting that TRBV7-9 might be associated with the disease phenotype.

In summary, polymorphism of TCR CDR3 in patients with vitiligo is significantly decreased, and TRBV7-9 may be associated with the disease phenotype. In this study, from the perspective of gene cloning, a new pathogenesis of vitiligo has been explained. However, there

Analysis of CDR3 polymorphism of TCR in vitiligo patients



Figure 3. Analysis of CDR3 amino acid. A: Length distribution of total clonotype and unique clonotype; B: Distribution of sample correlations; C: Distribution of amino acid composition ratio of all clonotype CDR3; D: Structural and functional analysis of two groups.

are still some deficiencies in the study, such as the small number of cases and no real verification in a larger range of *in vitro* and *in vivo* experiments. Furthermore, the characteristics of the TCR CDR3 against antigens were not clarified, therefore it is difficult to clearly reveal the specific immune response mechanisms of vitiligo. It is believed that as the research on the TCR CDR3 polymorphism continues, clinical understanding of vitiligo will be clearer.



Figure 4. Structure similarity, expression similarity and V gene expression of hyper-expressed clonotype sequences. A: Analysis of the expression quantity of each sample on hyper-expressed clone; B: Analysis of V gene expression.

Acknowledgements

This work was supported by the Science and Technology Planning Project of Shenzhen City (No. JCYJ20140416094256893).

Disclosure of conflict of interest

None.

Address correspondence to: Qin He, Department of Dermatology, The Eighth Affiliated Hospital, Sun Yatsen University, No. 3025 Shennan Middle Road, Shenzhen 518033, Guangdong Province, China. Tel: +86-0755-83980805; E-mail: heqin733@126.com

References

- [1] Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV and Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol 2015; 151: 42-50.
- [2] Pei T, Zheng C, Huang C, Chen X, Guo Z, Fu Y, Liu J and Wang Y. Systematic understanding the mechanisms of vitiligo pathogenesis and its treatment by Qubaibabuqi formula. J Ethnopharmacol 2016; 190: 272-287.
- [3] Tembhre MK, Parihar AS, Sharma VK, Sharma A, Chattopadhyay P and Gupta S. Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation. Br J Dermatol 2015; 172: 940-950.

- [4] Craiglow BG and King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 2015; 151: 1110-1112.
- [5] Li S, Yao W, Pan Q, Tang X, Zhao S, Wang W, Zhu Z, Gao J, Sheng Y, Zhou F, Zheng X, Zuo X, Sun L and Zhang A. Association analysis revealed one susceptibility locus for vitiligo with immune-related diseases in the Chinese Han population. Immunogenetics 2015; 67: 347-354.
- [6] Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, Tomasic G, Soria JC, Champiat S, Texier M, Lanoy E and Robert C. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51.
- [7] Hou X, Wang M, Lu C, Xie Q, Cui G, Chen J, Du Y, Dai Y and Diao H. Analysis of the repertoire features of TCR beta Chain CDR3 in human by high-throughput sequencing. Cell Physiol Biochem 2016; 39: 651-667.
- [8] Cao X, Wa Q, Wang Q, Li L, Liu X, An L, Cai R, Du M, Qiu Y, Han J, Wang C, Wang X, Guo C, Lu Y and Ma X. High throughput sequencing reveals the diversity of TRB-CDR3 repertoire in patients with psoriasis vulgaris. Int Immunopharmacol 2016; 40: 487-491.
- [9] Guo C, Wang Q, Cao X, Yang Y, Liu X, An L, Cai R, Du M, Wang G, Qiu Y, Peng Z, Han J, Ni S, Tan X, Jin L, Yu S, Wang H, Wang C, Wang X and Ma X. High-throughput sequencing reveals immunological characteristics of the TRB-/IgH-CDR3 region of umbilical cord blood. J Pediatr 2016; 176: 69-78.

- [10] He XY. Primary analysis of composition and characteristics of peripheral blood T cells TRBV F&P gene family CDR3 between mother and baby by CE&HTSb technology. Zunyi Medical College 2011.
- [11] Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA and Birlea SA. Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol 2015; 135: 2068-2076.
- [12] Benzekri L, Hmamouchi I and Gauthier Y. Possible patterns of epidermal melanocyte disappearance in nonsegmental vitiligo: a clinicopathological study. Br J Dermatol 2015; 172: 331-336.
- [13] Silpa-Archa N, Griffith JL, Huggins RH, Henderson MD, Kerr HA, Jacobsen G, Mulekar SV, Lim HW and Hamzavi IH. Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas. J Am Acad Dermatol 2017; 77: 318-327.
- [14] Pauken KE, Nelson CE, Martinov T, Spanier JA, Heffernan JR, Sahli NL, Quarnstrom CF, Osum KC, Schenkel JM, Jenkins MK, Blazar BR, Vezys V and Fife BT. Cutting edge: identification of autoreactive CD4⁺ and CD8⁺ T cell subsets resistant to PD-1 pathway blockade. J Immunol 2015; 194: 3551-3555.
- [15] Listowska M, Glac W, Grembecka B, Grzybowska M and Wrona D. Changes in blood CD4⁺ T and CD8⁺ T lymphocytes in stressed rats pretreated chronically with desipramine are more pronounced after chronic open field stress challenge. J Neuroimmunol 2015; 282: 54-62.

- [16] Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, Mehrotra S and Le Poole IC. CCL22 to activate treg migration and suppress depigmentation in vitiligo. J Invest Dermatol 2015; 135: 1574-1580.
- [17] Junqi WU, Jiang Y, Zhang S and Hospital JC. Peripheral melanoma antigen-specific CD8~⁺ T cells, regulatory T cells and natural killer T cells in patients with vitiligo. Zhejiang Medical Journal 2015.
- [18] Li HM, Hiroi T, Zhang Y, Shi A, Chen G, De S, Metter EJ, Wood WH 3rd, Sharov A, Milner JD, Becker KG, Zhan M and Weng NP. TCRbeta repertoire of CD4⁺ and CD8⁺ T cells is distinct in richness, distribution, and CDR3 amino acid composition. J Leukoc Biol 2016; 99: 505-513.
- [19] Shao H, Lin Y, Wang T, Ou Y, Shen H, Tao C, Wu F, Zhang W, Bo H, Wang H and Huang S. Identification of peptide-specific TCR genes by in vitro peptide stimulation and CDR3 length polymorphism analysis. Cancer Lett 2015; 363: 83-91.
- [20] Sui W, Hou X, Zou G, Che W, Yang M, Zheng C, Liu F, Chen P, Wei X, Lai L and Dai Y. Composition and variation analysis of the TCR betachain CDR3 repertoire in systemic lupus erythematosus using high-throughput sequencing. Mol Immunol 2015; 67: 455-464.